HCPCS Level II code J9042 denotes a 1 mg unit of brentuximab vedotin, an injectable antineoplastic agent used in oncology infusion settings. Nationally, billing for high-cost oncology biologics like brentuximab influences site-of-care decisions, patient cost-sharing, and payer coverage policies. This code is essential for accurate claims, provider reimbursement, and drug utilization tracking in outpatient infusion centers and hospital outpatient departments.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of brentuximab vedotin, typical sites of service, and what to expect in claims workflows. The publication provides benchmarks for unit reporting and discusses common billing considerations tied to injectable chemotherapy codes.

The report also summarizes policy and coding updates relevant to HCPCS Level II billing for antineoplastic agents, outlines documentation elements typically associated with oncology infusions, and highlights areas where payers commonly apply medical necessity and prior authorization criteria. Data not available in the input will be noted where applicable.